initi neutral great compani neutral stock valuat
initi coverag share neutral rate price
target base ep believ premium peer
median ep justifi given portfolio align dental
spin-off recent acquisit believ underli busi well-
posit danah busi system synergi sourc growth
improv lead strong revenu growth gross margin oper margin
expans appreci growth improv opportun
warrant premium multipl remain sidelin valuat
portfolio align solid histori high-growth acquisit includ
pall phenomenex well integr believ pend ge
biopharma acquisit synergist attract base biopharma histor
high-growth profil discount purchas price vs peer median ev/ebitda
acquisit adopt danah busi system platform approach continu
improv focus gross oper margin expans core growth
 invest pall exampl well-impl db
integr oper margin expans sinc acquir
share gain opportun think continu leverag core
busi strength diagnost believ cepheid extend market leadership via
larg menu id/std test addit water qualiti busi hach
trojan chemtreat consist outperform respect industri growth
rate believ trend continu innov invigor
go-to-market approach expand market e-commerc platform moreov
busi posit well potenti market soft
high-growth end market/region penetr expand high growth
end market region via innov acquisit core beckman
continu launch new complementari product autom sampl prep danah
expand synthet biolog acquisit labcyt think
two benefit channel touchpoint well provid synergi
complementari busi
invest thesi believ great compani remain neutral
valuat manag remain activ portfolio reevalu pend ge
biopharma acquisit dental spin-off go forward anticip growth driven
core busi strength well acquisit team solid track record
integr improv db implement
ep
debt total capit
competit regul reimburs acquisit integr
conglomer focus healthcar environment product
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
initi coverag share neutral rate price target
believ acquisit spin-off dental busi
repres compani align synergist portfolio posit scale expans
high-growth end market genom gene therapi region establish local
manufactur china believ share deserv premium multipl
premium peer median long-term growth driver place addit
anticip margin expans better capit alloc follow fortiv spin-off well
continu implement acquisit strong acquisit histori recent
announc ge biopharma histor integr busi well pall
manag focu continu acquisit return sharehold via buyback
dividend find acquisit attract synergist near-term
target struggl ge gave manag opportun acquir attract synergist
asset reason valuat manag anticip busi grow annual
valuat ebitda discount multipl comp median
multipl busi well posit growth intermedi long-term
opinion like manag track record acquir compani high-growth end
market short term think beckman coulter cepheid share gain opportun
life scienc diagnost market beckman coulter vitro diagnost brand
oper razor/razorblad busi model gener revenu consum
instrument mani busi use model lead attract
gross margin profil cepheid acquir due strong
foothold molecular diagnost market particularli high growth end market sexual
transmit diseas infecti diseas opportun gain share continu
adopt novel instrument genexpert addit growth driver includ enhanc capit
alloc specif acquisit compani high-growth end market margin
expans continu implement past new acquisit danah busi system
led oper effici across busi line addit spin-off dental
segment help margin histor lower busi
page
price target base ep estim believ
premium multipl justifi given posit gain share high growth end
markets/region strong brand acquisition/integr histori maintain
strong competit posit life scienc beckman ge pend diagnost cepheid
page
current valuationsdiversifi ls dxrevenueebitdaev/ebitdaep cagrp/etickercompanypricemarket
danah corpor design manufactur market profession medic industri
commerci product servic research develop manufactur sale
distribut servic administr facil locat countri across
busi compani implement danah busi system achiev unifi set
goal qualiti cost growth innov danah broken four segment
diagnost instrument reagent consum softwar servic clinic lab molecular
critic care anatom patholog diagnost life scienc tool studi gene protein
metabolit cell better understand diseas treatment test new drug use mass
spectrometri cellular analysi filtrat microscopi environment appli solut
tool protect resourc includ water qualiti product identif danah fourth
segment dental spun independ public compani second half
like constant evalu portfolio recent decis spin dental
anoth good exampl disciplin opinion compani take step strateg
align busi unit acquisit divestur februari compani
announc acquisit view synergist
exist portfolio deploy acquir integr dna technolog
announc decis spin dental busi focu life scienc
diagnost environment appli solut segment excit compani
provid ad valu consum use high growth applic molecular biolog
gene edit synthet biolog
cellular analysi lab autom
page
leader life scienc market per manag share
revenu life scienc segment life scienc segment repres
revenu exclud dental offer instrument reagent mass
spectrometri cellular analysi includ lab autom centrifug biopharmaceut
workflow filtrat microscopi laser scan compound surgic sampl prep
product within life scienc consum make revenu vs
instrument reflect razor/razorblad model histor grown segment
acquir compani secular growth tailwind attract scale aspect page
exhibit exampl includ ab sciex molecular devic beckman coulter life
scienc pall phenomenex expect
close life scienc segment grew organ report
model life scienc growth
page
announc acquisit ge life scienc biopharma busi februari
cash purchas net tax benefit financ cash transact
equiti offer possibl debt offer and/or new credit facil
remaind cash hand deal expect close
ge biopharma provid instrument consum softwar support research
discoveri process develop manufactur workflow biopharmaceut drug
develop instrument consum servic
see synergist portfolio alreadi identifi
synergist cost save realiz within year particularli see synergi
pall ge process chromatographi complementari upstream pall filtrat busi
give danah greater posit across workflow high-growth applic includ
monoclon antibodi vaccin gene therapi project addit think ge biopharma
end-to-end bioprocess solut drive solid near-term growth
manag expect gener annual revenu
reflect bioprocess revenu split cell cultur media singl use
technolog lab develop system consum chromatographi
product remain anticip includ lab filtrat genom consum
manag believ grow annual recur revenu
expect similar annual core growth go forward
subsidiari ab sciex molecular devic manufactur mass spectromet relat
consum chromatographi column sampl prep extract product well relat
analyt system micropl reader reagent softwar product use drug
discoveri therapeut develop clinic test food beverag qualiti test
environment test complet outright ownership ab sciex acquisit
life technolog corpor md inc share compani
stake ab sciex jv estim ab sciex repres life scienc revenu
total revenu ex dental grown compound-annual-growth-rate sinc acquir
estim mass spectrometri market ab sciex
share believ market continu see healthi growth grown compound-annual-growth-rate
past year ab sciex grow compound-annual-growth-rate time manag believ
sciex recent take share grow benefit
industri healthi growth market share gain driven sciex new mass
spec benchtop instrument instrument offer two variat one biotherapeut
food environment forens scienc
page
beckman coulter life scienc offer instrument consum aid analysi
genom protein cellular inform product includ sampl prep centrifug
capillari electrophoresi liquid handl flow cytometri particl character
beckman coulter life scienc busi acquir part beckman coulter
instrument consum use govern academ pharma applic
estim beckman revenu deriv life scienc research beckman life
scienc repres life scienc revenu total revenu
exclud dental estim busi grown annual sinc acquisit
enter filtrat segment pall acquisit segment consist
two busi group life scienc industri pall filtrat product use life
scienc busi process drug discoveri develop regulatori valid
product filtrat product also use food beverag market hospit
help control spread infect pall life scienc busi provid filtrat separ
purif solut use remov contamin separ substanc liquid solid
gase
estim pall revenu split roughli life scienc industri
applic filtrat product use raw materi process fluid wast stream
pall product also prolong life industri equip attract end market
semiconductor aerospac oil refineri estim pall repres revenu
exclud dental life scienc revenu grown annual sinc
acquir
phenomenex offer high gross margin estim may improv
db implement separ purif consum health research
environment market phenomenex product involv blood sampl liquid ga
chromatographi among other clinic pharmaceut environment applic
separ
page
life scienc segment establish acquir leica microsystem
busi manufactur microscop imag system compani microscop
fleet includ laser scan compound surgic well specimen prepar product
estim leica microsystem repres life scienc segment revenu
total revenu exclud dental grown annual sinc acquir
estim microscopi market leica share
integr acquir manufactur custom dna
rna oligonucleotid use academ biopharma research biotechnolog agricultur
clinic diagnost pharmaceut develop end market view synthet biolog
excit opportun catalyst long-term growth genom reagent market
market per manag grown annual past two year driven
gene edit qpcr given attract applic believ growth
modest assumpt genom reagent panel like grow doubl
digit see acceler driven custom rna dna oligo gene fragment
particularli synthet biolog applic cost declin crispr gene edit product
agricultur applic idt revenu annual april
expect idt busi benefit implement danah busi system
particularli db tool infrastructur channel/relationship synergi boost
busi commerci effort opinion manag state alreadi made
meaning progress sale funnel manag common db theme integr
reagent offer cost-effect highli sensit specif high throughput workflow requir
applic cripsr gene edit agricultur trait select believ idt
reagent best-in-class high throughput sequenc reason idt product
popular high-throughput system limit research implement
compon creat custom primer support exampl thermo fisher
run thermo ion
manag announc acquisit labcyt earn call labcyt
offer acoust liquid handl technolog elimin pipet contactless reduc
volum liquid movement yield precis amount higher frequenc yield
smaller droplet reduc costli reagent
acoust liquid handl use drug discoveri synthet biolog scale genom
research person medicin cancer therapi select believ labcyt
technolog complement entir life scienc portfolio believ obviou
custom synergi interestingli labcyt technolog also use popul
sequenc project univers helsinki institut molecular medicin finland
read full synthet biolog report
page
diagnost segment repres revenu exclud dental
compet market per manag broken four product line clinic
lab molecular critic care anatom patholog clinic lab busi manufactur
market biomed test instrument system relat consum use
evalu analyz sampl bodi fluid cell substanc clinic lab instrument
includ chemistri immunoassay hematolog flow cytometri microbiolog autom
molecular diagnost cepheid brand acquir critic care diagnost use
lab poc environ rapidli measur critic paramet blood gase
electrolyt glucos test anatom patholog busi offer chemic immune-
stain instrument relat consum tissu relat instrument consum slide
relat instrument imag relat instrument well relat softwar solut model
diagnost growth
manufactur biomed test instrument system relat consum
use evalu analyz bodi fluid cell substanc use diagnosi
diseas product use hospit outpati physician offic product includ
chemistri immunoassay hematolog current subject recal flow cytometri
microbiolog autom molecular diagnost system product
critic care product includ instrument relat consum servic use lab
poc environ measur blood gase electrolyt metabolit cardiac marker anemia
high sensit glucos test
page
leica biosystem offer instrument relat consum use entir workflow
patholog lab product includ chemic immune-stain tissu embed
process slice instrument reagent relat consum slide cover slip
microscop camera breast biopsi instrument softwar
diagnost side beckman coulter includ chemistri immunoassay hematolog
urinalysi microbiolog blood bank protein chemistri disciplin sepsi detect
reproduct health cardiovascular diseas anemia drug monitor detect
estim diagnost repres beckman coulter revenu beckman coulter
diagnost repres total revenu exclud dental
acquir vision system split leica two separ report
segment leica microsystem leica biosystem leica biosystem develop instrument
suppli patholog applic estim leica biosystem repres
leica busi revenu total revenu exclud dental diagnost
radiomet manufactur blood ga analyz estim busi grown high
singl digit annual sinc acquir repres diagnost
cepheid manufactur market molecular diagnost instrument system relat
consum genexpert autom mdx test platform offer larg menu limit
hand time minut rapid turnaround hour three year sinc danah
acquir cepheid genexpert still best-in-class autom turnaround menu cepheid
genexpert largest instal base system molecular ivd kit market pjc
estim sever sample-in answer-out competitor develop
meridian believ cephi larg menu extend market leadership id/std
test estim cepheid revenu exclud dental
page
danah environment appli solut segment includ product servic protect
resourc safeti food water suppli
provid instrument servic disinfect system ultra-pur potabl
industri wast ground sourc ocean water residenti commerci municip industri
natur resourc applic segment born acquisit dr lang hach
compani late compet market water qualiti market per
manag revenu segment grown annual sinc
manag estim achiev annual growth mid-single-digit model water
grow
hach provid solut instrument consum measur water qualiti hach product
use measur water qualiti municip drink water wastewat industri
applic engin consult industri applic includ beverag chemic
gener pulp paper revenu driven spectrophotomet associ
estim hach revenu exclud dental grown
annual sinc water test instrument cycl long year hach
attract recur revenu razor/razorblad busi model creat sticki custom
opinion estim hach grow consist manag mid-single-
digit growth outlook think share gain lead growth higher
industri low singl digit addit think water test stabl busi provid
downsid protect unfavor macroeconom environ
page
oper multipl brand suppli instrument disinfect system
treat water trojan product typic downstream infrastructur project
govern municip estim trojan grown annual sinc
though sinc busi larg project-driven time revenu vari saw
jump revenu due larg municip project set busi strong year
estim trojan revenu exclud dental
danah second water treatment busi chemtreat chemtreat focus larg industri
manufactur maritim metal mine off-shore plate power gener pulp paper
estim chemtreat grown annual sinc estim chemtreat
revenu exclud dental
product identif busi provid equip softwar servic consum
variou color appear manag packag design qualiti manag print
mark code traceabl applic consum pharma industri applic
help user offer busi expertis inspir virtual select
specifi formul measur color appear typic custom includ
consum good pharma paint plastic textil retail graphic design firm
packag printer convert revenu market per
manag estim product id grown annual past year
danah videojet busi provid code mark solut includ track trace
technolog busi similar model hach estim recur
revenu relat specif consum relat videojet equip busi
also well posit econom cycl given regulatori natur food
two color busi esko x-rite think two busi complement
custom need complet workflow x-rite manufactur market support innov
color solut measur system softwar color standard servic x-rite
paint plastic textil dental medic
page
danah primari capit deploy object acquisit attract end market
region believ manag strong aptitud deal success implement
busi system cultur februari announc
acquisit acquir largest acquisit
sinc acquir cepheid acquir complementari bolt-on busi
well exampl beckman life scienc acquir flow cytomet develop xitogen
acquisit expand beckman cytometri offer allow xitogen access
beckman distribut channel common theme acquisit
danah oper cultur manageri decis defin compani danah
busi system oper db similar toyota way manag
constantli reevalu manufactur process db run basi improv cost
structur expand gross margin lower sale reinvest top line
growth healthi sale market strong custom relationship target
competit advantag steadi gross margin expans primarili driven product
engin supplier manag labor product import creat maintain
custom relationship histor believ success implement db
within acquisit see exampl db also strive innov manag
believ reinvest growth believ focu custom relationship
key maintain competit advantag continu look attract acquisit
opportun exampl db implement includ
pall sinc implement db expand oper margin
track deliv cost save
ge biopharma manag believ theyv identifi initi annual cost
save realiz within three year
page
danah targetannouncementtransactiondescriptiong develop manufactur workflow biopharmaceut separ purificationbeckman scienc diagnost instrument consum net tax benefit exhibit
sale servic rep countri implement strong sale forc
danah distribut network help creat maintain custom relationship believ
way differenti across busi line addit product differenti previous
discuss reinvest sale market import part db platform
think sale team good job respect call point well util synergi
exist sinc revenu growth outpac sell administr growth
page
model revenu reflect organ growth report
growth model life scienc growth organ
revenu driven acquisit organ pall life scienc
ab sciex estim diagnost grow organ revenu driven
cepheid estim environment appli solut grow organ
revenu model organ growth life scienc
organ growth report growth driven ge biopharma diagnost organ
growth environment appli solut organ growth
walk model gm expans driven dental
spin-off continu db implement pall anticip
oper margin improv estim ep estim
oper margin expans db implement dental spin ge
biopharma integr lead ep
follow acquisit estim significantli increas
leverag net debt-to-ebitda estim howev strong cash
gener profil histor fit manag primari goal acquisit return
sharehold form buyback dividend manag financ acquisit via
cash hand also histor borrow acquir pall maintain
healthi balanc sheet manag said comfort leverag ratio
finish net debt posit cash equival
debt go forward assum borrow anticip ge
biopharma acquisit assum interest rate rais per guidanc continu
believ solid cash flow profil meet manag object
pend acquisit model oper cash flow
acquisit translat free cash flow per
share forecast oper cash flow free cash flow per
page
thoma joyc serv danah board sinc mr joyc held leadership role
sinc join year compani includ market manufactur
gener manag promot group execut corpor offic
ceo
matthew mcgrew succeed daniel coma cfo jan mr coma
serv dentalco spin gradual transit toward retir mr mcgrew start
director financ respons
report segment group cfo sinc
page
face competit across oper segment includ agil thermo fisher bio-
compani
offer least one compet line instrument mass spectromet microscopi
gas/liquid chromatographi etc differenti instrument perform
custom relationship instrument cycl includ upgrades/innov new competit
launch could affect sale one sever product repres risk
mani product requir regulatori approv fda ce prior commerci
later expect regulatori product approv repres risk futur product launch time
sell countri world-wide conduct busi multipl local currenc
cni eur jpi repres largest exposur compani mitig risk
implement sg and/or manufactur multipl ou locat china foreign
exchang volatil repres risk forward revenu ep project
may take signific amount debt financ acquisit
estim net debt/ebitda compani histor gener strong cash
flow may difficult market condit chang
page
million except share per share data
updat
good sold
good sold
good sold
net incom common
current disclosur inform compani locat
